US FDA says the collaborative approach taken by an independent security researcher and Johnson & Johnson/Animas in responding to a potentially fatal cybersecurity vulnerability with the firm's Animas OneTouch Ping insulin pump should be a model for the industry that aligns with the agency's recent draft guidance.
In a case straight out of FDA's playbook for tackling cybersecurity vulnerabilities, Johnson & Johnson recently announced it is working with the hacker who discovered a security loophole on their Animas Corp.OneTouch Ping insulin pump to mitigate the problem.
Jay Radcliffe, a senior security consultant and researcher at Rapid7, discovered that he was able to break into the OneTouch...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor, which must be replaced just once a year. Capable of being integrated with compatible insulin pumps as part of an automated insulin delivery system, the fully implantable device lasts 185 days longer than the Eversense E3 sensor and far outstrips competing CGMs, which last only for 10-14 days.
With the reversal of the Chevron doctrine in June, lower courts will now have more say in deciding regulatory statutes when the language is murky. But will that open the door to more legal challenges from the healthcare industry against government regulations it finds unfavorable? A pair of legal experts recently discussed the potential implications of the Court’s decision.
The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.
This week, a Delaware court awarded Auris Health shareholders $1bn in a lawsuit against Johnson & Johnson; Abbott recalled some FreeStyle Libre 3 sensors; and McKesson purchased a controlling interest in a Florida cancer care chain.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Nearly 80 documents have been posted on the tracker since its last update.
The Food and Drug Administration’s final guidance outlines the agency’s thinking for sponsors submitting de novo requests electronically, which they must starting in October 2025.
